BHVN news

Biohaven Ltd. has entered into an exclusive license agreement with SK Biopharmaceuticals for Kv7 activators. The agreement, effective August 26, 2026, grants SKBP rights to develop, manufacture, and commercialize drugs in the CNS and oncology fields.

Biohavens new extracellular protein degraders showed robust clinical safety and efficacy, paving the way for multiple registrational programs. Clinical data for the epilepsy drug opakalim remains on track.

Biohaven promoted Dr. David Pirman to Executive Vice President and Head of Discovery, while Bruce Car transitioned to Chief Innovation Officer. This leadership shift aims to accelerate drug innovation and external collaborations.

Biohaven presented clinical data showing opakalim, a Kv7.2/7.3 activator, achieved a 3-fold prolongation in time to seizure occurrence in idiopathic generalized epilepsy and 54% seizure reduction in focal epilepsy patients with a favorable tolerability profile. The positive interim results support t…